Medical Editor: John P. Cunha, DO, FACOEP
Skelid (tiludronate disodium) is a bisphosphonate used to treat Paget's disease of bone. The brand name Skelid is discontinued, but generic versions may be available. Common side effects of Skelid (tiludronate disodium) include:
A single 400-mg daily oral dose of Skelid, taken with 6 to 8 ounces of plain water only, should be administered for a period of 3 months. Skelid may interact with other drugs. Tell your doctor all medications and supplements you use. Caution is advised if you are pregnant or planning to become pregnant in the future. Skelid may stay in your body for many years. Its effects on a fetus are unknown. Consult your doctor before starting treatment with Skelid. It is unknown if this drug passes into breast milk, and the effect on a nursing infant is unknown. Consult your doctor before breastfeeding.
Our Skelid (tiludronate disodium) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Skelid (Tiludronate)
The safety of SKELID (tiludronate) has been studied in more than 1100 patients, and the adverse experience profile is similar between controlled and uncontrolled clinical trials. Adverse events occurring in placebo-controlled trials of pagetic patients treated with SKELID (tiludronate) 400 mg/day are presented in the table below.
Adverse events associated with SKELID (tiludronate) usually have been mild, and generally have not required discontinuation of therapy. In two placebo-controlled trials, 1.3% of patients receiving 400 mg SKELID (tiludronate) and 5.4% of patients receiving placebo discontinued therapy due to any clinical adverse event.
Adverse Eventsa (%) Reportedb in >
2% of Pagetic Patients from Placebo-Controlled Studies
| SKELID (tiludronate)
|BODY AS A WHOLE|
|Central and Peripheral Nervous Systems|
|Metabolic and Nutritional|
|Vitamin D Deficiency||2.7||2.7|
|Upper Respiratory Tract Infection||5.3||14.9|
|Skin and Appendage|
a Reported using WHO terminology
b All events reported, irrespective of causality
Other adverse events not listed in the table above but reported in ≥ 1% of pagetic patients treated with SKELID (tiludronate) in all clinical trials of at least one month duration, regardless of dose and causality assessment, are listed below. The adverse event terms within each body system are listed in the order of decreasing frequency occurring in the population.
Central and Peripheral Nervous Systems: Vertigo, involuntary muscle contractions
Musculoskeletal: Fracture pathological
Respiratory System: Bronchitis
Skin and Appendages: Pruritus, increased sweating
Urinary System: Urinary tract infection
Vascular (extracardiac): Flushing
Stevens-Johnson type syndrome has been observed rarely; the causality relationship of this to SKELID (tiludronate) has not been established.
Read the entire FDA prescribing information for Skelid (Tiludronate)
© Skelid Patient Information is supplied by Cerner Multum, Inc. and Skelid Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.